GURUFOCUS.COM » STOCK LIST » USA » NAS » United Therapeutics Corp (NAS:UTHR) » Definitions » Price-to-Tangible-Book
Switch to:

United Therapeutics Price-to-Tangible-Book

: 2.36 (As of Today)
View and export this data going back to 1999. Start your Free Trial

As of today (2022-08-07), United Therapeutics's share price is $221.65. United Therapeutics's Tangible Book per Share of Jun. 2022 for the quarter that ended in Jun. 2022 was $93.95. Hence, United Therapeutics's Price to Tangible Book Ratio of today is 2.36.

The historical rank and industry rank for United Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

UTHR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16   Med: 3.14   Max: 18.16
Current: 2.36

During the past 13 years, United Therapeutics's highest Price to Tangible Book Ratio was 18.16. The lowest was 1.16. And the median was 3.14.

UTHR's Price-to-Tangible-Book is ranked better than
56.09% of 1346 companies
in the Biotechnology industry
Industry Median: 2.74 vs UTHR: 2.36

A closely related ratio is called PB Ratio. As of today, United Therapeutics's share price is $221.65. United Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2022 was $94.93. Hence, United Therapeutics's P/B Ratio of today is 2.33.


United Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for United Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Tangible-Book
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 1.81 1.47 2.09 2.49

United Therapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Price-to-Tangible-Book Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 2.20 2.49 1.97 2.51

Competitive Comparison

For the Biotechnology subindustry, United Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

United Therapeutics Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, United Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Price-to-Tangible-Book falls into.



United Therapeutics Price-to-Tangible-Book Calculation

United Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2022 )
=221.65/93.95
=2.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


United Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics Business Description

United Therapeutics logo
Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
Benkowitz Michael officer: President and COO C/O UNITED THERAPEUTICS CORP 1040 SPRING STREET SILVER SPRING MD 20910
Maxwell Linda director 1040 SPRING STREET SILVER SPRING NC 27709
Thompson Tommy G director 7711 CARONDELET ST. LOUIS MO 63105
Mesa Nilda director C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING MD 20910
Klein Katherine J director STEINBERG HALL-DIETRICH HALL 3620 LOCUST WALK PHILADELPHIA PA 19104
Giltner Richard director C/O UNITED THERAPEUTICS CORPORTION 1735 CONNECTICUT AVE. NW WASHINGTON DC 20009
Olian Judy D. director 2000 AVENUE OF THE STARS 12TH FL LOS ANGELES CA 90067
Edgemond James officer: CFO and Treasurer 1040 SPRING STREET SILVER SPRING MD 20910
Zaccardelli David officer: EVP & Chief Operating Officer 300 TRI STATE INTERNATIONAL SUITE 272 LINCOLNSHIRE IL 60069
Eli Lilly & Co 10 percent owner LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Ferrari John Maxim officer: CFO & Treasurer 1110 SPRING STREET SILVER SPRING MD 20910
Patusky Christopher director
Hicks Henry Beecher Iii director C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910
Gray R Paul director C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910
Dwek Raymond director

United Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)